# A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

> **NCT03596294** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Clazosentan
- **DRUG:** Rifampicin
- **OTHER:** Saline (0.9% sodium chloride)

## Key facts

- **NCT ID:** NCT03596294
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-19
- **Primary completion:** 2018-08-03
- **Final completion:** 2018-08-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03596294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03596294, "A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03596294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*